Has David Ridley, MD received payments from drug or device companies?

Yes. Drug and device makers reported $26,296 in general payments to David Ridley, MD across 58 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Ridley, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Ridley, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Ridley, MD

Rheumatology · Eagan, MNNPI 1659396000

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $16,366 of the $26,296 with a category attached, or 62.2%. 14 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 42.9% of the total. Reporting peaked in 2019 at $10,113 and has fallen 82.1% since, to $1,813 in 2025. Among rheumatology clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$26,296in general payments, 2019–2025

Across 58 payments — averaging $453.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$11K
Amgen$5K
Gilead$5K
Janssen Research & Development, LLC$2K
Fresenius Kabi USA, LLC$2K
Johnson & Johnson$816
plus $777 from 8 others

$1,181,740in research payments, 2019–2025

Across 162 payments — averaging $7294.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Amgen$521K
E.r. Squibb & Sons, L.L.C.$325K
Gilead$168K
Janssen Research & Development, LLC$70K
UCB SA$46K
Bristol Myers Squibb$13K
plus $39K from 6 others

What the payments were for

Consulting fees$16,36662%
Speaking & faculty fees$5,40021%
Grants$2401%
Travel & lodging$2,81011%
Food & beverage$1,4806%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	15	$11,292
Amgen(2 entities)	6	$5,473
Gilead	7	$4,645
Janssen Research & Development, LLC	11	$1,732
Fresenius Kabi USA, LLC	1	$1,560
Johnson & Johnson	6	$816
Janssen Scientific Affairs, LLC	3	$409
AbbVie	2	$255
Boehringer Ingelheim	2	$43
Pfizer	1	$15
Daiichi Sankyo Inc.	1	$14
AstraZeneca	1	$14
Actelion Pharmaceuticals US, Inc.	1	$14
Genentech USA, Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ORENCIA$7,008
Otezla$5,400
Tremfya$1,159
STELARA$750
SIMPONI ARIA$750
Rinvoq$240

How this compares

$26,296 in reported general payments places this provider in the 90th percentile of 121 rheumatology providers in Minnesota.

See all rheumatology providers in Minnesota →

Medicare billing

Part B allowed, 2024

$1,895,162

Medicare patients

244

Services billed

110,006

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Humira(Cf) PenAdalimumab	17	$205,226
Enbrel SureclickEtanercept	11	$84,071
Hydroxychloroquine Sulfate	266	$16,044
MethotrexateMethotrexate Sodium	334	$13,603
Azathioprine	163	$9,205
Leflunomide	134	$8,355
Mercaptopurine	17	$3,698
Pilocarpine Hcl	40	$3,349
Mycophenolate Mofetil	15	$1,677
Leucovorin Calcium	33	$1,648
Sulfasalazine	31	$1,368
Allopurinol	45	$860
Prednisone	55	$653
Spironolactone	44	$637
Gabapentin	20	$604

Paid to pharmacies, not to this prescriber.

Other rheumatology in Eagan

Elvia Moreta FreireEagan$7K
Asim KhanMaple Grove$1.2M
Parastoo FazeliMinneapolis$149K
Robert TierneySt Louis Park$137K
Ali SajjadMaplewood$87K
Steven YtterbergRochester$87K
Cornelia WeyandRochester$59K
Eric MattesonRochester$51K
Jeffrey WilsonEdina$49K
John DavisRochester$32K

See the full list for Minnesota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →